

**Author Relationships With Industry and Other Entities (Comprehensive) — 2018 ACC Expert Consensus  
Decision Pathway on Tobacco Cessation Treatment**

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Rajat S. Barua <i>(Chair)</i>	Kansas City VA Medical Center—Director, Cardiovascular Research & Interventional Cardiology;  University of Kansas School of Medicine—Associate Professor of Medicine	None	None	None	None	None	None
Nancy A. Rigotti <i>(Vice-Chair)</i>	Massachusetts General Hospital— Professor of Medicine	<ul style="list-style-type: none"> <li>● Pfizer*</li> <li>● Achieve Life Sciences</li> </ul>	None	None	<ul style="list-style-type: none"> <li>● NIH/NHLBI†</li> <li>● Pfizer</li> </ul>	<ul style="list-style-type: none"> <li>● National Academies of Science, Engineering and Medicine*</li> <li>● UpToDate†</li> </ul>	None
Neal L. Benowitz	UCSF Center Tobacco Control Research/Education— Professor of Medicine	<ul style="list-style-type: none"> <li>● Pfizer</li> <li>● Achieve Life Sciences</li> </ul>	None	None	None	<ul style="list-style-type: none"> <li>● Pfizer*</li> <li>● Up to Date</li> <li>● McGraw Hill</li> </ul>	<ul style="list-style-type: none"> <li>● 2016, Plaintiff, tobacco litigation†</li> </ul>
K. Michael Cummings	Medical University of South Carolina—Professor, Department of Psychiatry & Behavioral Sciences;  Co-leader Hollings Cancer Center Tobacco Research Program	<ul style="list-style-type: none"> <li>● Pfizer</li> </ul>	None	None	<ul style="list-style-type: none"> <li>● NIH/NCI/NIDA†</li> </ul>	<ul style="list-style-type: none"> <li>● Pfizer†</li> </ul>	<ul style="list-style-type: none"> <li>● 2016, Plaintiff, tobacco litigation†</li> </ul>
Mohammad-Ali Jazayeri	University of Kansas Medical Center— Fellow, Division of Cardiovascular Diseases	None	None	None	None	None	None
Pamela Bowe Morris	Medical University of South Carolina—Associate Professor of Medicine, Division of Cardiology	<ul style="list-style-type: none"> <li>● Amgen</li> <li>● AstraZeneca</li> <li>● Sanofi Regeneron</li> </ul>	None	None	<ul style="list-style-type: none"> <li>● Amgen</li> </ul>	None	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Elizabeth V. Ratchford	Johns Hopkins University School of Medicine— Director, Johns Hopkins Center for Vascular Medicine; Associate Professor of Medicine	None	None			None	None
Linda Sarna	UCLA School of Nursing— Dean & Professor, Lulu Wolf Hassenplug Endowed Chair	• NIH	None	None	• International Society of Nurses in Cancer Care		None
Eric C. Stecker	Oregon Health & Science University—Associate Professor of Medicine	None	None	• Hygeia/Desi MD†	• AHA† • Medical Research Foundation of Oregon†	• ARCA Biopharma‡ • Sentre Heart‡ • Medtronic‡	None
Barbara S. Wiggins	Medical University of South Carolina—Clinical Pharmacy Specialist in Cardiology	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

\* No financial benefit.

† Significant relationship.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.